What is the share price of Vimta Labs Ltd (VIMTALABS) today?
The share price of VIMTALABS as on 24th April 2025 is ₹1153. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Vimta Labs Ltd (VIMTALABS) share?
The past returns of Vimta Labs Ltd (VIMTALABS) share are- Past 1 week: 7.36%
- Past 1 month: -10.10%
- Past 3 months: 32.39%
- Past 6 months: 110.21%
- Past 1 year: 126.43%
- Past 3 years: 203.98%
- Past 5 years: 1297.58%
What are the peers or stocks similar to Vimta Labs Ltd (VIMTALABS)?
The peers or stocks similar to Vimta Labs Ltd (VIMTALABS) include:What is the dividend yield % of Vimta Labs Ltd (VIMTALABS) share?
The current dividend yield of Vimta Labs Ltd (VIMTALABS) is 0.19.What is the market cap of Vimta Labs Ltd (VIMTALABS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Vimta Labs Ltd (VIMTALABS) is ₹2330.62 Cr as of 24th April 2025.What is the 52 week high and low of Vimta Labs Ltd (VIMTALABS) share?
The 52-week high of Vimta Labs Ltd (VIMTALABS) is ₹1178 and the 52-week low is ₹420.What is the PE and PB ratio of Vimta Labs Ltd (VIMTALABS) stock?
The P/E (price-to-earnings) ratio of Vimta Labs Ltd (VIMTALABS) is 56.83. The P/B (price-to-book) ratio is 7.29.Which sector does Vimta Labs Ltd (VIMTALABS) belong to?
Vimta Labs Ltd (VIMTALABS) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.How to buy Vimta Labs Ltd (VIMTALABS) shares?
You can directly buy Vimta Labs Ltd (VIMTALABS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Vimta Labs Ltd
VIMTALABS Share Price
1,153.0010.00% (+104.80)
VIMTALABS Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
VIMTALABS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 37.96 | 7.29 | 0.19% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.61 | 6.44 | 0.53% |
VIMTALABS Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
VIMTALABS Company Profile
Vimta Labs Limited is engaged in providing testing and contract research services in the fields of clinical and pre-clinical studies, clinical reference, analytical testing, advanced molecular biology and environmental studies.
Investor Presentation
View olderVIMTALABS Similar Stocks (Peers)
Compare with peersDIVISLAB
PE Ratio
98.30
1Y Return
62.97%
Buy Reco %
43.48
SYNGENE
PE Ratio
58.96
1Y Return
5.85%
Buy Reco %
75.00
AARTIPHARM
PE Ratio
30.80
1Y Return
45.09%
Buy Reco %
—
PE Ratio
-21.35
1Y Return
7.72%
Buy Reco %
—
BROOKS
PE Ratio
-21.16
1Y Return
40.45%
Buy Reco %
—
VIMTALABS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
VIMTALABS Stock Summary · November 2024
Vimta Labs demonstrated robust financial performance in the first half of FY '25, achieving a year-on-year growth of 26.4% driven by its pharmaceutical services, which now account for approximately 70% of revenue. Despite facing inflationary pressures and operational challenges from transitioning to new facilities, the company remains optimistic about future growth, particularly in clinical trials and complex generics. The divestment of its diagnostics business is expected to enhance focus and resource optimization, while ongoing capacity expansions aim to support a targeted quarterly run rate of INR 500 crores by FY '26. Management is cautiously optimistic about maintaining EBITDA margins around 35%, even as they navigate the evolving market dynamics and strategic shifts in service offerings.
Key Points on Vimtalabs Stock
VIMTALABS Stock Growth Drivers
8Strong Financial Performance
Vimta Labs reported significant financial growth, with total income reaching INR 854 million in Q2
Successful Divestment and Focus on Core Services
The divestment of the diagnostics services business to Thyrocare Technologies Ltd. has allowed Vimta Labs
VIMTALABS Stock Challenges
3Operational Challenges in Food Segment
The food segment is currently facing significant operational challenges due to internal transitions, specifically the
Short-term Revenue Risks
The ongoing transitions within the food segment pose a risk of short-term business loss, as
VIMTALABS Forecasts
Price
Revenue
Earnings
VIMTALABS Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeVIMTALABS Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeVIMTALABS Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeVIMTALABS
Income
Balance Sheet
Cash Flow
Annual Normal View
VIMTALABS Income Statement
Annual Normal View
| Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 183.73 | 211.51 | 279.73 | 321.63 | 322.27 | 336.31 | ||||||
Raw Materials | 32.41 | 35.25 | 54.81 | 44.13 | 48.69 | 219.29 | ||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Employee Cost | 57.63 | 57.80 | 71.42 | 86.32 | 95.30 | |||||||
| Selling & Administrative Expenses | 26.50 | 21.73 | 28.56 | 43.23 | 38.83 | |||||||
| Operating & Other expenses | 34.22 | 42.94 | 44.43 | 49.60 | 48.65 | |||||||
EBITDA | 32.97 | 53.79 | 80.51 | 98.35 | 90.80 | 117.02 | ||||||
| Depreciation/Amortization | 20.93 | 23.08 | 23.33 | 30.71 | 34.20 | 34.17 | ||||||
| PBIT | 12.04 | 30.71 | 57.18 | 67.64 | 56.60 | 82.85 | ||||||
| Interest & Other Items | 3.77 | 2.17 | 1.50 | 2.65 | 2.12 | 1.99 | ||||||
| PBT | 8.27 | 28.54 | 55.68 | 64.99 | 54.48 | 80.86 | ||||||
| Taxes & Other Items | 1.42 | 7.14 | 14.36 | 16.83 | 13.47 | 19.47 | ||||||
| Net Income | 6.85 | 21.40 | 41.32 | 48.16 | 41.01 | 61.39 | ||||||
| EPS | 3.10 | 9.68 | 18.69 | 21.77 | 18.51 | 27.69 | ||||||
| DPS | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | ||||||
| Payout ratio | 0.00 | 0.21 | 0.11 | 0.09 | 0.11 | 0.07 |
VIMTALABS Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2025
Investor Presentation
Nov 8PDF
VIMTALABS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Vimta Labs Ltd | 56.83 | 7.29 | 0.19% |
| Divi's Laboratories Ltd | 98.30 | 11.59 | 0.51% |
| Syngene International Ltd | 58.96 | 7.06 | 0.17% |
| Aarti Pharmalabs Ltd | 30.80 | 3.80 | 0.41% |
VIMTALABS Stock Price Comparison
Compare VIMTALABS with any stock or ETFCompare VIMTALABS with any stock or ETF
VIMTALABS
VIMTALABS Shareholdings
VIMTALABS Promoter Holdings Trend
VIMTALABS Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.65%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
VIMTALABS Shareholding Pattern
VIMTALABS Shareholding History
Foreign Institutions
Mutual Funds Invested in VIMTALABS
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 2 Mutual Funds holding Vimta Labs Ltd
| Funds (Top 2) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.06% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 89/110 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0000% | Percentage of the fund’s portfolio invested in the stock 0.00% | Change in the portfolio weight of the stock over the last 3 months -1.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 50/68 (-1) |
Compare 3-month MF holding change on Screener
smallcases containing VIMTALABS stock
Looks like this stock is not in any smallcase yet.
VIMTALABS Events
VIMTALABS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
VIMTALABS Upcoming Dividends
No upcoming dividends are available
VIMTALABS Past Dividends
Cash Dividend
Ex DateEx DateJul 11, 2024
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jul 11, 2024
Cash Dividend
Ex DateEx DateJun 21, 2023
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 21, 2023
Cash Dividend
Ex DateEx DateJun 16, 2022
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 16, 2022
Cash Dividend
Ex DateEx DateJun 25, 2021
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 25, 2021
Cash Dividend
Ex DateEx DateJul 18, 2019
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jul 18, 2019
VIMTALABS Stock News & Opinions
Articles & Videos
Corporate
Vimta Labs declare Quarterly Result
Vimta Labs will hold a meeting of the Board of Directors of the Company on 28 April 2025.Powered by Capital Market - Live
6 hours agoCapital Market - Live
Corporate
Vimta Labs allots 11,726 equity shares under ESOP
Vimta Labs has allotted 11,726 equity shares under ESOP on 20 March 2025. With this allotment, the paid up equity share capital has increased to Rs. 4,44,69,024 consisting of 2,22,34,512 equity shares having a face value of Rs. 2 each. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Vimta Labs consolidated net profit rises 112.24% in the December 2024 quarter
Net profit of Vimta Labs rose 112.24% to Rs 21.50 crore in the quarter ended December 2024 as against Rs 10.13 crore during the previous quarter ended December 2023. Sales rose 20.57% to Rs 89.92 crore in the quarter ended December 2024 as against Rs 74.58 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales89.9274.58 21 OPM %36.7932.05 - PBDT33.7224.07 40 PBT23.9215.64 53 NP21.5010.13 112 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Vimta Labs schedules board meeting
Vimta Labs will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Vimta Labs consolidated net profit rises 140.92% in the September 2024 quarter
Net profit of Vimta Labs rose 140.92% to Rs 15.25 crore in the quarter ended September 2024 as against Rs 6.33 crore during the previous quarter ended September 2023. Sales rose 29.30% to Rs 84.74 crore in the quarter ended September 2024 as against Rs 65.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales84.7465.54 29 OPM %35.3026.56 - PBDT30.1818.84 60 PBT21.8910.19 115 NP15.256.33 141 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Vimta Labs to hold board meeting
Vimta Labs will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Vimta Labs completes sale of its diagnostic and pathological services business
Vimta Labs has completed the sale and transfer of its diagnostic and pathological services business as a going concern to Thyrocare Technologies on 11 October 2024. Powered by Capital Market - Live
6 months agoCapital Market - Live
Vimta Labs consolidated net profit rises 0.66% in the June 2024 quarter
9 months agoBusiness Standard
Vimta Labs Consolidated March 2023 Net Sales at Rs 81.82 crore, up 10.44% Y-o-Y
1 year agoMoneycontrol
Stocks to watch on May 3, 2023
1 year agoThe Hindu Businessline
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant